Cell Reports volume 3, issue 2, P275-276 2013 DOI: 10.1016/j.celrep.2013.02.001 View full text
|
|
Share
Emerson Lim, Edward P. Gelmann

Abstract: Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.